Introduction

Amyotrophic lateral sclerosis (ALS) is a lethal, progressive neurodegenerative disease that affects upper and lower motor neurons. Its prevalence in Mexico ranges from 5000 to 7000 patients according to Martínez et al. In France, it is estimated at 2.5 per 100,000 population. The age of onset is approximately 47.5 years, with survival of up to 58.9 months after diagnosis. Otero et al. reported that ALS accounts for more than 90 % of cases of motor neuron diseases in Mexico, with the phenotype including signs of upper or lower motor neuron.

Genetic and molecular epidemiology

ALS occurs sporadically (SALS) in 90 to 95 % of cases and family-wise (FALS) in 5 to 10 %. Sporadic forms are more often observed outside the European continent. FALS forms are associated with a large number of pleiotropic genes (Table 1), which results in clinical and pathological phenotypes overlap. Different inheritance patterns have also been described. The genes most frequently associated with FALS are SOD1 Tau. Mutations in the SOD1 gene explain 2 % of cases affected by SALS, out of which approximately 10 % are inherited as a dominant autosomal pattern with high penetrance after the sixth decade. Clinical phenotype is similar in FALS and SALS cases. It should be noted that Scandinavians’ p.D90A mutation is transmitted with a recessive pattern (Table 1).

SOD1 classical mutations in ALS are p.G37T, p.L38V, p.G41S, p.G41D, p.H43R, p.G85R, p.G93C, p.G93A, p.E100G, p.L106V and p. I113Y, which produce changes in SOD1, thus decreasing enzymatic activity. In an Italian population, the p.G12R, p.G41S,
Table 1. Types of ALS according to the involved gene and its inheritance pattern

| Type   | Symbol   | Gene                                      | Locus       | FALS | SALS | Inheritance |
|--------|----------|-------------------------------------------|-------------|------|------|-------------|
| ALS 1  | SOD1     | Cu/Zn superoxide dismutase 1              | 21q22.11    | Yes  | Yes  | AD and AR   |
| ALS 2  | ALS2     | Alsin                                     | 2q33.2      | Yes  | No   | AR          |
| ALS 3  | ALS3     | Alsin 3                                   | 18q21       | Yes  | No   | AD          |
| ALS 4  | SETX     | Senataxin                                 | 9q34.13     | Yes  | Yes  | AD          |
| ALS 5  | SPAST    | Spastin                                   | 2p24        | Yes  | Yes  | AR          |
| ALS 6  | FUS      | t-derived gene (12;16)                    | 16p11.2     | Yes  | Yes  | AD          |
| ALS 7  | ALS7     | Alsin 7                                   | 20p13       | Yes  | No   | AD          |
| ALS 8  | VAPB     | B-protein associated with vesicle membrane-associated protein | 20q13.33    | Yes  | No   | AD          |
| ALS 9  | ANG      | Angiogenin                                | 14q11.1     | Yes  | Yes  | AD          |
| ALS 10 | TARDBP   | TAR DNA-binding protein                   | 1p36.22     | Yes  | Yes  | AD          |
| ALS 11 | FIG4     | Homologous to FIG4, SCA1 lipid phosphatase-containing domain | 6q21        | Yes  | Yes  | AD          |
| ALS 12 | OPTN     | Optineurin                                | 10p13       | Yes  | Yes  | AD and AR   |
| ALS 13 | ATXN2    | Ataxin 2                                  | 12q23-24.1  | No   | Yes  | AD          |
| ALS 14 | VCP      | Valosin-containing protein                | 9p13        | Yes  | No   | AD          |
| ALS 15 | UBQLN2   | Ubiquitin 2                               | Xp11.21     | Yes  | No   | Dominant X-linked |
| ALS 16 | SigmAR1  | Non-opioid sigma 1 intracellular receptor  | 9p13        | Yes  | No   | AR          |
| ALS 17 | CHMP28   | ---                                       | 3p11.2      | No   | Yes  | AD          |
| ALS 18 | PPN1     | Prolin 1                                  | 17p13.3     | No   | Yes  | AD          |
| ALS 19 | ERBB4    | Viral avian erythroblastic leukemia oncogene homolog | 2q34       | Yes  | No   | AD          |
| ALS 20 | HNRNPA1  | Heterogeneous nuclear ribonucleoprotein A1 | 12q13.13    | Yes  | Yes  | AD and AR   |
| ALS 21 | MATR3    | Matrin 3                                  | 5q31.2      | Yes  | No   | AD          |
| ALS-DFT2 | CHCHD10 | Coiled-Coil-Helix-Coiled-Coil-Helix Domain-Containing Protein 10 | 9q21-2q22   | Yes  | No   | AD          |
| ALS-DFT1 | C9orf7 2 | Chromosome 9 open reading framework 72    | 9p21.2      | Yes  | Yes  | AD          |
| Risk   | UNC13A   | Caenorhabditis elegans A homolog          | 19p13.11    | No   | Yes  | AD          |
| ---    | DAO      | D-amino acid oxidase                      | 12q24       | Yes  | No   | AD          |
| ---    | DCTN1    | Dinactin                                  | 2p13        | Yes  | Yes  | AD          |
| ---    | NEFH     | Neurofilament constitutive 200-kDa heavy chain | 22q12.1    | Yes  | Yes  | AD          |
| ---    | PRPH     | Peripherin                                | 12q12       | No   | Yes  | AD          |
| ---    | SQSTM1   | Sequestosome 1                            | 5q35        | Yes  | Yes  | AD          |
| ---    | TAF15    | TATA box binding protein-associated factor | 17q11.1-q11.2 | Yes  | No   | AD          |
| ---    | SPAST    | Spastin                                   | 2p24        | No   | Yes  | AD          |
| ---    | ELP3     | Homolog elongation protein 3 (Saccharomyces cerevisiae) | 8p21.1 | No   | Yes  | AD          |
| ---    | LMNB1    | Laminin B1                                | 5q23.2      | Yes  | No   | AD          |

ALS = amyotrophic lateral sclerosis, SALS = sporadic amyotrophic lateral sclerosis, FALS = familial amyotrophic lateral sclerosis, AD = autosomal dominant, AR = autosomal recessive. --- Is used in the type column when, despite the fact that the gene was associated, it has not had a sufficient number of reports to assign a specific name to the disease associated with it; in the inheritance column it is used to note that a specific inheritance form has not been determined. Table created based on OMIM data and http://alsod.iop.kcl.ac.uk/
p.L114F and p.D90A mutations were found in seven out of 39 patients with atypical-phenotype FALS. In addition, a synonymous p.S59S variant was identified in a patient with ALS.7

In another case series, nt34A→C intron 3 polymorphism was found in 17 out of 264 patients (6.4 %), and the IVS3+62T→C variant was identified in one FALS patient. Total frequency of SOD1 gene mutations (17.9 %) in FALS cases was comparable to that found in other studies, with a similar sample size of ALS cases. Among the FALS cases, the most common mutation was p.G41S.11

In another cross-sectional Italian population cohort, eight out of 38 patients (21 %) with FALS and five out of 175 (3 %) with SALS had nonsense mutations in the SOD1 gene. Two additional mutations were identified, one in exon 4 (p.L84F) in a familial case and the second in exon 3 (p.G72S) in a sporadic patient.12

The role of the SOD1 enzyme

The SOD1 gene has its locus at 21q22.11, it has a length of 9310 base pairs (bp) and is composed of five exons; it encodes the superoxide dismutase (SOD1) enzyme. This protein has 153 amino acid residues with a weight of 16 kDa13 and oxidoreductase and peroxidase activities. Its quaternary structure is formed by barrel-shaped beta strands arranged in a Greek key motif.14 Each homodimer constitutes a unit called A, B, C, D or E and has the capacity to associate with four other units, reaching a configuration similar to a “dog femoral bone”; in turn, these structures tend to group forming asymmetric units, which generate a structure that resembles a honeycomb.15

The SOD1 enzyme is cytoplasmic, and catalyzes the conversion of superoxide with nitric oxide (NO) to the peroxidized anion (ONOO-) form, which generates HO and NOx toxic radicals.14-16 This mechanism might induce neurodegeneration due to free radical accumulation, causing cell death.7

Through immunohistochemistry, SOD1 has been shown to be abundantly distributed in motor neurons, interneurons and sensory neurons in the spinal cord,17 with a punctate pattern in the motor and sensory portions of the cranial nerve nuclei, the soma, as well as in proximal dendrites and terminal axons in unaffected individuals;18 it has been diffusely found in the cortex, hippocampus and amygdala.19 On the other hand, a more abundant expression of SOD1 has been demonstrated in patients affected by ALS. These evidences strongly support the gain-of-function hypothesis with toxic effect rather than haploinsufficiency.18,20

Mutations in the SOD1 gene

Most mutations reported in SOD1 are nucleotide changes with sense or intron reading frame shifts.2-3 The effect of enzyme activity percentage is a poorly studied field, which limits genotype-phenotype correlation determination. Among the largest studies that have reported the frequency of mutations in the SOD1 gene is the cohort of 2045 non-Hispanic white patients with FALS and SALS, among which SOD1 mutations were found in 148 cases. The most prevalent mutations associated with the disease in the SOD1 gene were p.A4V, in 41 % of patients, p.Ile113Tyr in 16 % and intron mutations in 11 %. Sixteen exon mutations were found (p.K8V, p.F20C, p.Q22L, p.H48R, p.T54R, p.S59I, p.V87A, T88DTAD, p.A89T, p.V97M, p.S105DSL, p.V118L, p.D124G, p.G141X, p.G147R and p.I151S), which correspond to a frequency of 10.81 %. In 2.7 % of cases with SALS, four patients were detected with the following mutations: p.G37R, p.D90A and p.E100G.21

In another cohort of non-Hispanic white subjects with FALS, the p.A4V mutation in exon 1 was the most common (32 %). On the other hand, the p.G37R p.G93A, p.E100G and p.I151Y mutations had a frequency of 8 %. The study of molecular coupling (docking) of these variants reveals the alteration of the interactions for the contact of the doublets and the beta barrel dimer. The red blood cells of the heterozygous index cases had less than 50 % activity, which consistent with a structurally defective SOD dimer.22

In clinical practice, genotype-phenotype correlation studies are important (Table 2); for example, in a FALS cohort in an Asian Japanese population, four different sense mutations were reported in exons 2, 4 and 5 of the SOD1 gene in five families: p.H46R, p.L84V, p.I104F and p.V148I. Patients with the p.H46R mutation showed a benign clinical course and stereotyped progression of muscle weakness and leg atrophy. p.L84V carriers have a very similar clinical course of disease, with the age of onset being earlier in males than in females. Patients with p.I104F showed wide ranges of age of onset and duration, with ophthalmoparesis and sensory involvement in one patient. Those with the p.V148I mutation showed an earlier age at onset and first variable symptoms within the family. Although the LMN sign was evident in all cases, hyperreflexia varied between patients with different
Table 2. Genotype-phenotype correlation for mutations in SOD1

| Type   | Type of mutation | Frequency (%) | Affected (n) | Clinical phenotype               | Enzyme activity % | Population                              | Reference |
|--------|------------------|---------------|--------------|----------------------------------|-------------------|-----------------------------------------|-----------|
| SALS   | p.E21K           | 1.5           | 1/67         | Definitive diagnosis             | Not reported      | European, Scottish                      | 6         |
| SALS   | p.I113Y          | 87            | 20/23        | Definitive diagnosis             | Not reported      | Non-Hispanic White                      | 8         |
| SALS   | IVS3+34 A > C    | 5.3           | 14/264       | Definitive diagnosis             | Not reported      | European, Italian                       | 11        |
| SALS   | p.S59S           | 0.4           | 1/264        | Definitive diagnosis             | Not reported      | European, Italian                       | 11        |
| SALS   | p.G72S           | 2.6           | 1/38         | Definitive diagnosis             | Not reported      | European, English                       | 12        |
| SALS   | p.G37R           | 1.4           | 2/148        | Definitive diagnosis             | Not reported      | Non-Hispanic White                      | 22        |
| SALS   | p.D90A           | 0.7           | 1/148        | Definitive diagnosis             | Not reported      | Non-Hispanic White                      | 22        |
| SALS   | p.A4V            | 7.7           | 1/13         | Definitive diagnosis             | Not reported      | Caucasian, Canadian                     | 24        |
| SALS   | p.G72C           | 7.7           | 1/13         | Definitive diagnosis             | Not reported      | Caucasian, Canadian                     | 24        |
| SALS   | p.D76Y           | 7.7           | 1/13         | Definitive diagnosis             | Not reported      | Caucasian, Canadian                     | 24        |
| SALS   | p.D90A           | 7.7           | 1/13         | Definitive diagnosis             | Not reported      | Caucasian, Canadian                     | 24        |
| FALS   | p.D90A           | 7.7           | 1/13         | Definitive diagnosis             | Not reported      | Caucasian, Canadian                     | 24        |
| FALS   | p.D90A           | 7.7           | 1/39         | Atypical phenotype               | Not reported      | European, Italian                       | 11        |
| SALS   | p.C111Y          | 7.7           | 1/13         | Definitive diagnosis             | Not reported      | Caucasian, Canadian                     | 24        |
| SALS   | p.I113Y          | 7.7           | 1/13         | Definitive diagnosis             | Not reported      | Caucasian, Canadian                     | 24        |
| FALS   | p.I113Y          | 13            | 9/67         | Definitive diagnosis             | Not reported      | European, Scottish                      | 6         |
| FALS   | p.I113Y          | 8             | 2/25         | Severe progressive neurogenic muscular atrophy | Lower than 50% | Non-Hispanic White                       | 22        |
| FALS   | p.I113Y          | 16            | 24/148       | Definitive diagnosis             | Not reported      | Non-Hispanic White                      | 21        |
| FALS   | p.G93R           | 1.5           | 1/67         | Definitive diagnosis             | Not reported      | European, Scottish                      | 6         |
| FALS   | p.E100G          | 1.5           | 1/67         | Definitive diagnosis             | Not reported      | European, Scottish                      | 6         |
| FALS   | p.G12R           | 7.7           | 1/39         | Slowly progressive disease course | Not reported      | European, Italian                       | 11        |
| FALS   | p.L114F          | 7.7           | 1/39         | Slowly progressive course        | Not reported      | European, Italian                       | 11        |
| FALS   | IVS3+62 T        | 0.4           | 1/14         | Definitive diagnosis             | Not reported      | European, Italian                       | 11        |
| FALS   | p.G72C           | 7.7           | 1/13         | Definitive diagnosis             | Not reported      | Caucasian, Canadian                     | 24        |

(Continues)
Bulbar paralysis was common in p.I104F carriers, but not in those with p.H46R. Red blood cell SOD1 activity was severely reduced with p.I104F and p.V148I, but slightly reduced with p.H46R.

Another study with this approach in 254 patients with FALS and SALS in the province of British Columbia, Canada, showed, in 13 patients (5.1 %), the p.A4V, p.G72C, p.D76Y, p.D90A, p.C111Y and p.I113T mutations in SOD1, both in FALS and SALS. There were clinical discordances even between patients with the same mutation. This supports the hypothesis that ALS is a heterogeneous disorder where genetics, the environment and aging interrelate to form the final clinical phenotype.

In an Asian Iranian cohort of 60 patients with ALS (four families), SOD1 mutations were found in 11.7 %, 38.5 % of FALS subjects and in 4.25 % of SALS cases; the screening identified p.D90A homozygous in all related families. Haplotype analysis suggests that Iranian patients might share a common founder with the famous recessive Scandinavian p.D90A allele. Other mutations identified were p.L84F, p.A4Y and p.I113Y. In an Italian

| Type | Type of mutation | Frequency (%) | Affected (n) | Clinical phenotype | Enzyme activity | Population | Reference |
|------|-----------------|---------------|--------------|--------------------|----------------|------------|-----------|
| FALS | p.D76Y          | 7.7           | 1/13         | Definitive diagnosis | Not reported  | Caucasian, Canadian | 24 |
| FALS | p.C111Y         | 7.7           | 1/13         | Definitive diagnosis | Not reported  | Caucasian, Canadian | 24 |
| FALS | p.G37R          | 8             | 2/25         | Severe progressive neurogenic muscular atrophy | Lower than 50% | Non-Hispanic White | 22 |
| FALS | p.G33A          | 8             | 2/25         | Severe progressive neurogenic muscular atrophy | Lower than 50% | Non-Hispanic White | 22 |
| FALS | p.E100G         | 8             | 2/25         | Severe progressive neurogenic muscular atrophy | Lower than 50% | Non-Hispanic White | 22 |
| FALS | p.L84V          | 10            | 3/30         | Early age of onset | Lower than 50% | Asian Japanese | 23 |
| FALS | p.H46R          | 6.7           | 2/30         | Benign clinical course | Lower than 50% | Asian Japanese | 23 |
| FALS | p.I104F         | 6.7           | 2/30         | Ophthalmoparesis and sensorial involvement | Severe reduction, lower than 10% | Asian Japanese | 23 |
| FALS | p.A4V           | 15.28         | 2/13         | Definitive diagnosis | Not reported  | Caucasian, Canadian | 24 |
| FALS | p.I113Y         | 13            | 3/23         | Definitive diagnosis | Not reported  | Non-Hispanic White | 8 |
| FALS | IVS3+34 A > C   | 1.14          | 3/264        | Definitive diagnosis | Not reported  | European, Italian | 11 |
| FALS | p.G41S          | 30.8          | 4/39         | Rapidly progressive course with severe cognitive impairment | Not reported  | European, Italian | 11 |
| FALS | p.V148I         | 13.3          | 4/30         | Early onset | Lower than 10% | Asian Japanese | 23 |
| FALS | p.A4V           | 32            | 8/25         | Severe progressive neurogenic muscular atrophy | Lower than 50% | Non-Hispanic White | 22 |
| FALS | p.G41S          | 100           | 9/9          | Severe phenotype, rapidly progressive | Not reported  | European, Italian | 26 |
| FALS | p.D90A          | 38.5          | 12/60        | Definitive diagnosis | Not reported  | Asian, Iranian | 25 |
| FALS | p.L84F          | 2.6           | 1/38         | Definitive diagnosis | Not reported  | European, English | 12 |
| FALS | p.A4V           | 41            | 61/148       | Definitive diagnosis | Lower than 10% | Non-Hispanic White | 21 |

SALS = sporadic amyotrophic lateral sclerosis, FALS = familial amyotrophic lateral sclerosis.
population, one case of FALS was found to bear the heterozygous mutation p.L106, whose clinical presentation was characterized by relatively early age of onset, and bulbar and spinal involvement. SOD1 pathogenic mechanism in neuronal death varies; lines of evidence suggest poor protein folding. p.G10R mutation docking showed strong destabilization, which influences the strength of the dimer interface, generating toxic intracellular aggregates, which supports this theory.

In a case report of two Italian patients with ALS, apparently sporadic, heterozygous for the p.D90A mutation in SOD1, one patient experienced early sensory involvement. In six families with ALS, the p.G41S mutation was detected by direct sequencing. Clinical pattern of these patients was characterized for the spinal appearance of upper and lower motor neurons with early involvement, the appearance of bulbar signs in one year and death a few months later; average age at onset was 49.3 years and average duration of the disease was 0.9 years; a common haplotype was found for carriers of the mutation, which demonstrates a founding effect in Italy. Indeed, the p.G41S mutation is constantly related to a severe, rapidly progressive phenotype.

The following data were obtained from the aforementioned studies: total number of individuals affected by ALS was 2553, out of which 46 were FALS; in these cases, the most common mutations were p.I113T in 45.67 % and IVS3+34 A>C in 30.44 % (Fig. 1). In the FALS cases, the p.A4V, p.I113Y, p.D90A, p.L84F and p.G41S mutations were detected in 39.01, 21.43, 8.24, 7.69 and 7.14 %, respectively. Only two of the reviewed studies analyze the enzyme function with the mutations found in the affected population.

ALS is a complex disease

Genetic studies show that ALS is a complex disease due to molecular heterogeneity, there are more than 23 responsible genes that have a direct effect on the phenotype, as described in Table 1. More than 140 different mutations distributed in the five exons and introns of the SOD1 gene have been reported, with p.A4V being the most common mutation in familial cases, while in sporadic cases it is the p.I113T mutation. This supports ALS high polygenic component, as well as its molecular and allelic heterogeneity.
Disease presentation varies, with sporadic forms and familial variants that are transmitted with an autosomal dominant inheritance pattern; however, there are mutations that are transmitted with a recessive pattern. Even 85-year-old, completely asymptomatic individuals have been reported to be carriers of the p.D90A mutation, with this adding to the hypothesis on the existence of a complementary mechanism responsible for neurological damage in ALS.

It should be noted that the phenotype can differ depending on the region of the gene the mutations affect. There is not a clear genotype-phenotype correlation, due to differences in the presentation between familial and sporadic cases, as well as in intra-familial cases with the same mutation, which is attributed to variable expressivity or to modifier genes.

ALS has been postulated to be a conformational disease, since mutations in SOD1 lead to changes in the structure of the enzyme and affect its catalytic activity (activity lower than 50%), as well as to haploinsufficiency. On the other hand, accumulation of this protein with folding defects is related to mutations, which translates into gain-of-function with a toxic effect, known as negative dominant effect.

Studies of targeted mutagenesis analyzing haploinsufficiency and the negative dominant effect are limited; in future works, it will be important to investigate them in order to identify the clinical effect of the amino acid change in the structure of the active site, the allosteric region and other SOD1 functional domains.

**Advances in ALS genetics**

Through new generation sequencing, 20% of familial cases were found in the French population, with a frequency of 50% for SOD1 mutations, while in the English population the following mutations were found: p.C256G, p.G229T, p.A272C, p.A305G, p.C310T, p.G335A, p.T341C and p.A403G. Recently, a new c.791A>G mutation was found in the SETX gene in a woman with ALS of Hungarian ancestry. In a population with that same ancestry, new mutations in the SOD1 gene have been reported in sporadic cases, including p.K91R, p.V14M, p.D90A, p.L144F and p.L91R. Abnormal expansion of (GGGGCC)n of the C9ORF72 gene has also been found in up to 30% of SALS cases. The SOD1 and C9orf72 genes have the most important contribution in the pathogenesis of the disease. Currently, the new targets in ALS therapy are focused on protein homeostasis disruption, alterations in the biology of proteins that bind to RNA, as well as cytoskeleton dynamics defects.

**Frontiers in ALS research**

The new challenges in the study of ALS are the effect of epigenetic modifications, which might shed light on the age of onset, familial presentation or severity, to facilitate the identification of efficacious therapies, early diagnosis and potential therapeutic interventions at early stages. In Latin America, there is no research with information on ALS genetics. At the immune system level, the role of 19 cytokines has been explored, including adipin, adiponectin, IL-4 and IL-6 in relation to clinical severity and disease duration. Adipin was found to be elevated in cerebrospinal fluid; adiponectin showed a tendency towards higher concentrations. Certainly, more epidemiological studies on these interleukins are necessary in order to establish their prognostic value. This evidence may suggest that variants in the genes that code for these proteins can modify ALS clinical expression. Relevant clinical studies include a report of four cases of juvenile familial ALS and prolonged survival recently, our working group reported a case of ALS in Mexico, which was positive for a mutation in the MT-CYTB gene.

**Conclusions**

ALS is a complex genetic disease, which is reflected on its different inheritance patterns, mutational component, high penetrance, variable age of onset, and simultaneously-altered multiple metabolic pathways in patients with this disease. On the other hand, most mutations found in SOD1 are mainly responsible for FALS and one third of SALS cases. There are other genes that should be explored as a cause, especially in FALS: C9orf72 and SETX. At the clinical level in Mexico, proinflammatory cytokines could be prognostic markers, although it will be necessary to validate them.

**Conflict of interest**

There were no conflicts of interest by the authors.

**Acknowledgements**

To Conacyt, for the national sabbatical grant bestowed to Dr. Sergio A. Ramírez García, from Universidad de la Sierra Sur.
References

1. Woolley SC, Rush BK. Considerations for clinical neuropsychological evaluation in amyotrophic lateral sclerosis. Arch Clin Neuropsychol. 2017;32:906-916.
2. Couratier P, Marin B, Lautrette G, Nicol M, Preux PM. Epidemiology, clinical spectrum of ALS and differential diagnosis. Presse Med. 2014;43:538-548.
3. Volk AE, Weishaupl JH, Andersen PM, Ludolph AC, Kubisch C. Current knowledge and recent insights into the genetic basis of amyotrophic lateral sclerosis. Med Genet. 2018;30:252-258.
4. Rohrer JD, Isaacs AM, Mizielinska S, Mead S, Lashley T, Wray S, et al. C9orf72 expansions in frontotemporal dementia and amyotrophic lateral sclerosis. Lancet Neurol. 2015;14:291-301.
5. Bunton-Stayshy RN, Sacon RA, Fratta P, Fisher EM. SOD1 function and its implications for amyotrophic lateral sclerosis pathology: new and renauscent themes. Neuroscientist. 2015;21:519-529.
6. Jones CT, Brock DJ, Chancellor AM, Warlow CP, Swingler RJ. Cu/Zn superoxide dismutase (SOD1) mutations and sporadic amyotrophic lateral sclerosis. Lancet. 1993;342:1050-1051.
7. Schmitt ND, Agar JN. Parsing disease-relevant protein modifications from epiphenomena: perspective on the structural basis of SOD1-mediated ALS. J Mass Spectrom. 2017;52:480-491.
8. Kikugawa K, Nakano R, Inuzuka T, Kokubu Y, Naita Y, Kuzuhara S, et al. A missense mutation in the SOD1 gene in patients with amyotrophic lateral sclerosis from the Kii Peninsula and its vicinity, Japan. Neurogenetics. 1997;11:115-116.
9. Zhang CC, Zhu JX, Wan Y, Tan L, Wang HF, Yu JT, Tan L. Meta-analysis of the association between variants in MAPT and neurodegenerative diseases. Oncotarget. 2017;8:44994-45007.
10. Morello G, Spampinato AG, Cavallaro S. Molecular taxonomy of sporadic amyotrophic lateral sclerosis using disease-associated genes. Front Neurol. 2017;8:152.
11. Battistini S, Giannini F, Greco G, Bibbo G, Ferrara L, Marin V, et al. SOD1 mutations in amyotrophic lateral sclerosis. Results from a multi-center Italian study. J Neurol. 2005;252:782-788.
12. Chio A, Mazzini L, D’Alfonso S, Corrado L, Canosa A, Moglia C, et al. The multistep hypothesis of ALS revisited: the role of genetic mutations. Neurology. 2018;91:e635-e642.
13. Peters OM, Ghasemi M, Brown RH. Emerging mechanisms of molecular pathology in ALS. J Clin Invest. 2015;125:1767-1779.
14. Salem K, McCormick ML, Wendlandt E, Zhan F, Goel A. Copperzinc superoxide dismutase-mediated redox regulation of bortezomib resistance in multiple myeloma. Redox Biol. 2015;4:23-33.
15. Venkataramani V, Doepner TR, Willkommen D, Cahill CM, Xin Y, Ye G, et al. Manganese causes neurotoxic iron accumulation via translational repression of Amyloid precursor protein and H-Ferritin. J Neurochem. 2018;147:831-848.
16. Majzúnová M, Pakanová Z, Kvasnička P, Bališ P, Čačányiová S, Dovičová I. Age-dependent redox status in the brain stem of NO-deficient NO-congenic rats. J Biomed Sci. 2017;24:72.
17. Popović-Bijelić A, Mojoyi M, Stamenković J, Srečeková J, Andjus P, et al. Iron-sulfur cluster damage by the superoxide radical in neural tissues of the SOD1(G93A) ALS rat model. Free Radic Biol Med. 2016;96:313-322.
18. D’Ambrosi N, Cozzolino M, Carri MT. Neuroinflammation in Amyotrophic lateral sclerosis: role of redox (dys) regulation. Antioxid Redox Signal. 2018;29:15-36.
19. Pardo CA, Xu Z, Borchelt DR, Price DL, Sisodia SS, Cleveland DW. Superoxide dismutase is an abundant component in cell bodies, dendrites, and axons of motor neurons and in a subset of other neurons. Proc Natl Acad Sci U S A. 1995;92:854-858.
20. Carocci A, Catalano A, Sinicropi MS, Gerchen G. Oxidative stress and neurodegeneration: the involvement of iron. Biometals. 2018;31:715-735.
21. Andersen PM, Sims KB, Xin WW, Kiely R, O’Neill G, Ravits J, et al. Sixteen novel mutations in the Cu/Zn superoxide dismutase gene in amyotrophic lateral sclerosis: a decade of discoveries, defects and disputes. Amyotroph Lateral Scler Other Motor Neuron Disord. 2003;4:62-73.
22. Deng HX, Hentati A, Tainer JA, Iqbal Z, Gayababy A, Hung WY, et al. Amyotrophic lateral sclerosis and structural defects in Cu,Zn superoxide dismutase. Science. 1993;261:1047-1051.
23. Abe K, Aoki M, Ikeda M, Watanabe M, Hira S, Itoyama Y, et al. Clinical characteristics of familial amyotrophic lateral sclerosis with Cu/Zn superoxide dismutase gene mutations. J Neurol Sci. 1996;136:108-116.
24. Eisen A, Mezer MM, Stewart HG, Fabros M, Gibson G, Andersen PM, et al. SOD1 gene mutations in ALS patients from British Columbia, Canada: clinical features, neuropathology and ethical issues in management. Amyotroph Lateral Scler. 2008;9:108-119.
25. Alavi A, Nafissi M, Mohammadi S, Sadeghi B, Shamshiri H, et al. Genetic analysis and SOD1 mutation screening in Iranian amyotrophic lateral sclerosis patients. Neurobiol Aging. 2013;34:1515-8.
26. Battistini S, Rocci C, Giannini F, Calzavara S, Greco G, Del Corona A, et al. G41S SOD1 mutation: a common ancestor for six ALS Italian families with an aggressive phenotype. Amyotroph Lateral Scler. 2010;11:210-215.
27. Almasov NA, Ivanisenko NV, Taneja B, Taneja V, Ramachandran S, Ivanisenko VA. Improved regression model to predict an impact of SOD1 mutations on ALS patients survival time based on analysis of hydrogen bond stability. J Mol Graph Model. 2016;86:247-255.
28. Corcia P, Couratier P, Blasco H, Andres CR, Beltran S, Meinger V, et al. Genetics of amyotrophic lateral sclerosis. Rev Neurol (Paris). 2017;173:254-262.
29. Morgan S, Stathouv S, Sprowiero W, Jones AR, Shoai M, Hughes D, et al. A comprehensive analysis of rare genetic variation in amyotrophic lateral sclerosis in the UK. Brain. 2017;140:1611-1618.
30. Tripolzki K, Török D, Goudenêge D, Farkas K, Sulák A, Törtö K, et al. High-throughput sequencing revealed a novel SETX mutation in a Hungarian patient with amyotrophic lateral sclerosis. Brain Behav. 2017;7:e00669.
31. Tripolzki K, Csányi B, Nagy D, Ratti A, Tció C, Illányi V, et al. Genetic analysis of the SOD1 and C9ORF72 genes in Hungarian patients with amyotrophic lateral sclerosis. Neurobiol Aging. 2017;59:e1-195.e5.
32. Martin S, Al-Keifelat A, Al-Chalabi A. What causes amyotrophic lateral sclerosis? F1000Res. 2017;8:371.
33. Ghasemi M, Brown RH. Genetics of amyotrophic lateral sclerosis. Cold Spring Harb Perspect Med. 2018;8:pii.
34. Jiménez-Pacheco A, Franco JM, López S, Gómez-Zumaquero JM, Magdalena-Leal-Lasarte M, Caballero-Hernández DE, et al. Epigenetic mechanisms of gene regulation in amyotrophic lateral sclerosis. Adv Exp Med Biol. 2017;978:255-275.
35. Martínez HR, Escamilla CE, Camara CR, González MT, Tenorio JM, Hernández M. CSF concentrations of adipin and adiponectin in patients with amyotrophic lateral sclerosis. Acta Neurol Belg. 2017;117:379-383.
36. Martínez-HR, Parada JD, Meza MG, González MT, Moreno C, Escalerosis lateral amiotropica. Contribución de la neurología mexicana de 1998 a 2014. Rev Mex Neuroci. 2014;15:355-362.
37. Arriada N, Ríos C, Otero-Silico E, Corona-Vázquez T. ALS in a secluded region in Mexico possibly related to lead toxicity. Arch Neurosci. 2020;5:2-5.
38. Bresch S, Delmont E, Soriani MH, Desnuelle C. Electrodiagnostic criteria for early diagnosis of bulb-onset ALS: a comparison of El Escorial, revised El Escorial and Awaji algorithm. Rev Neurol (Paris). 2014;170:134-139.
39. Cervantes I, Ramírez S, García D. Amyotrophic lateral sclerosis positive mutation in the CYTB gene and negative for SOD1 and ATXN2. Rev Fac Med. 2017;65:377-378.